US Physician Paradigm Study Informs Decision-Making in Locally Advanced/Metastatic Urothelial Carcinoma - Episode 1

Overview of Locally Advanced/Metastatic Urothelial Carcinoma

July 7, 2022

Vinit Makkar, MD, provides a brief overview of locally advanced/metastatic urothelial carcinoma (la/mUC), available first-line (1L) and first-line maintenance (1LM) treatment options, and unmet needs in the field.

Now Viewing

EP. 1: Overview of Locally Advanced/Metastatic Urothelial Carcinoma

EP. 2: Scope and Methods of the PARADIGM Study and Expert Commentary on Treatment Decision-Making

EP. 3: Perspectives on First-Line Treatment Decision-Making for la/mUC: Results of The Targeted Literature Search and Qualitative Interviews

EP. 4: A Cross-Sectional Survey Reveals Physicians’ Treatment Patterns in First-Line and Maintenance Therapy for la/mUC

EP. 5: Key Factors Associated with First-Line and Maintenance Therapy Prescription Frequency

EP. 6: Key Takeaways from the PARADIGM Study